1. Home
  2. CRVS vs PSNL Comparison

CRVS vs PSNL Comparison

Compare CRVS & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$12.68

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Personalis Inc.

PSNL

Personalis Inc.

HOLD

Current Price

$10.04

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRVS
PSNL
Founded
2014
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2016
2019

Fundamental Metrics

Financial Performance
Metric
CRVS
PSNL
Price
$12.68
$10.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
5
Target Price
$30.17
$12.20
AVG Volume (30 Days)
1.3M
3.0M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
48.04
33.58
EPS
N/A
N/A
Revenue
N/A
$69,648,000.00
Revenue This Year
N/A
$15.34
Revenue Next Year
N/A
$41.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.71
$3.84
52 Week High
$26.95
$12.53

Technical Indicators

Market Signals
Indicator
CRVS
PSNL
Relative Strength Index (RSI) 52.58 56.83
Support Level $11.13 $7.26
Resistance Level $14.00 $11.28
Average True Range (ATR) 0.66 0.97
MACD 0.24 -0.15
Stochastic Oscillator 83.26 28.99

Price Performance

Historical Comparison
CRVS
PSNL

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

About PSNL Personalis Inc.

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Share on Social Networks: